Literature DB >> 14595654

Valproic acid increases SMN levels in spinal muscular atrophy patient cells.

Charlotte J Sumner1, Thanh N Huynh, Jennifer A Markowitz, J Stephen Perhac, Brenna Hill, Daniel D Coovert, Kristie Schussler, Xiaocun Chen, Jill Jarecki, Arthur H M Burghes, J Paul Taylor, Kenneth H Fischbeck.   

Abstract

Spinal muscular atrophy (SMA) is an inherited motor neuron disease caused by mutation of the telomeric copy of the survival motor neuron gene (SMN1). Although a centromeric copy of the survival motor neuron gene (SMN2) is retained in all patients with SMA, it differs from SMN1 at a critical nucleotide such that the majority of SMN2 transcripts lack exon 7 and encode an unstable, truncated protein. Here, we show that valproic acid increases levels of exon 7-containing SMN transcript and SMN protein in type I SMA patient-derived fibroblast cell lines. Valproic acid may increase SMN levels both by activating the SMN promoter and by preventing exon 7 skipping in SMN transcripts. Valproic acid and related compounds warrant further investigation as potential treatment for SMA.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14595654     DOI: 10.1002/ana.10743

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  102 in total

Review 1.  Motoneuron injury and repair: New perspectives on gonadal steroids as neurotherapeutics.

Authors:  Julie E Tetzlaff; Christopher B Huppenbauer; Lisa Tanzer; Thomas D Alexander; Kathryn J Jones
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

2.  In vivo selection reveals combinatorial controls that define a critical exon in the spinal muscular atrophy genes.

Authors:  Natalia N Singh; Elliot J Androphy; Ravindra N Singh
Journal:  RNA       Date:  2004-08       Impact factor: 4.942

Review 3.  Spinal muscular atrophy: an update on therapeutic progress.

Authors:  Joonbae Seo; Matthew D Howell; Natalia N Singh; Ravindra N Singh
Journal:  Biochim Biophys Acta       Date:  2013-08-27

Review 4.  Applicability of histone deacetylase inhibition for the treatment of spinal muscular atrophy.

Authors:  Sebastian Lunke; Assam El-Osta
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

5.  Development of histone deacetylase inhibitors as therapeutics for neurological disease.

Authors:  Joel M Gottesfeld; Massimo Pandolfo
Journal:  Future Neurol       Date:  2009-11-01

Review 6.  Better days are coming for Riley-Day patients.

Authors:  F C Luft
Journal:  J Mol Med (Berl)       Date:  2006-12-22       Impact factor: 4.599

7.  The survival of motor neurons protein determines the capacity for snRNP assembly: biochemical deficiency in spinal muscular atrophy.

Authors:  Lili Wan; Daniel J Battle; Jeongsik Yong; Amelie K Gubitz; Stephen J Kolb; Jin Wang; Gideon Dreyfuss
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

8.  The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells.

Authors:  Markus Riessland; Lars Brichta; Eric Hahnen; Brunhilde Wirth
Journal:  Hum Genet       Date:  2006-05-25       Impact factor: 4.132

Review 9.  Perspectives on clinical trials in spinal muscular atrophy.

Authors:  Kathryn J Swoboda; John T Kissel; Thomas O Crawford; Mark B Bromberg; Gyula Acsadi; Guy D'Anjou; Kristin J Krosschell; Sandra P Reyna; Mary K Schroth; Charles B Scott; Louise R Simard
Journal:  J Child Neurol       Date:  2007-08       Impact factor: 1.987

Review 10.  Multiple roles of HDAC inhibition in neurodegenerative conditions.

Authors:  De-Maw Chuang; Yan Leng; Zoya Marinova; Hyeon-Ju Kim; Chi-Tso Chiu
Journal:  Trends Neurosci       Date:  2009-09-21       Impact factor: 13.837

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.